Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: Seeking Alpha
However, they do not hold the rights for this cell therapy's commercialization. Furthermore, ATRA has suspended development of their pipeline, meaning there are few, if any, catalysts to justify buying in. Adventure_Photo/iStock via Getty Images Topline Summary Last time I took a look at Atara Biotherapeutics ( ATRA ), I was intrigued and optimistic about their allogeneic (non-self) CAR T-cell therapy, in a novel indication for engineered cell therapies. But that has been quite This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee o
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Atara Biotherapeutics: Q3 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Announces Third Quarter Financial Results and Operational ProgressBusiness Wire
- Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c-)" rating to a "sell (d+)" rating.MarketBeat
- Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)PR Newswire
ATRA
Earnings
- 11/12/25 - Beat
ATRA
Sec Filings
- 12/1/25 - Form 4
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- ATRA's page on the SEC website